International guidelines on access to biologic therapy: why the differences and which is best?

被引：10
作者：
Deighton, Chris [1 ]
Hyrich, Kimme [2 ,3 ]
机构：
[1] Derbyshire Royal Infirm, Dept Rheumatol, Derby DE1 2QY, England
[2] Univ Manchester, ARC Epidemiol Unit, Manchester, Lancs, England
[3] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England
来源：
NATURE CLINICAL PRACTICE RHEUMATOLOGY | 2008年 / 4卷 / 10期
关键词：
D O I：
10.1038/ncprheum0877
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：520 / 521
页数：2
相关论文
共 10 条
[1]   The NICE reappraisal of biologics in 2005: what rheumatologists need to know [J].
Bansback, NJ ;
Young, A ;
Brennan, A .
RHEUMATOLOGY, 2005, 44 (01) :3-4
[2]   Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again) [J].
Deighton, C. M. ;
George, E. ;
Kiely, P. D. W. ;
Ledingham, J. ;
Luqmani, R. A. ;
Scott, D. G. I. .
RHEUMATOLOGY, 2006, 45 (06) :649-652
[3]   Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis [J].
Fautrel, Bruno ;
Pham, Thao ;
Mouterde, Gael ;
Le Loet, Xavier ;
Goupille, Philippe ;
Guillemin, Francis ;
Ravaud, Philippe ;
Cantagrel, Alain ;
Dougados, Maxime ;
Puechal, Xavier ;
Sibilia, Jean ;
Soubrier, Martin ;
Mariette, Xavier ;
Combe, Bernard .
JOINT BONE SPINE, 2007, 74 (06) :627-637
[4]   Prescription practice of biological drugs in rheumatoid arthritis during the first 3 years of post-marketing use in Denmark and Norway: criteria are becoming less stringent [J].
Hjardem, E ;
Hetland, ML ;
Ostergaard, M ;
Krogh, NS ;
Kvien, TK .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1220-1223
[5]   Aspects of early arthritis - Biological therapy in early arthritis - overtreatment or the way to go? [J].
Ikeda, Kei ;
Cox, Sally ;
Emery, Paul .
ARTHRITIS RESEARCH & THERAPY, 2007, 9 (03)
[6]  
*NIH CLIN EXC, AD ET INFL TREATM RH
[7]  
*NIH CLIN EXC, AB TREAT RHEUM ARTHR
[8]   QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries [J].
Sokka, Tuulikki ;
Kautiainen, Hannu ;
Toloza, Sergio ;
Makinen, Heidi ;
Verstappen, Suzan M. M. ;
Hetland, Merete Lund ;
Naranjo, Antonio ;
Baecklund, Eva ;
Herborn, Gertraud ;
Rau, Rolf ;
Cazzato, Massimiliano ;
Gossec, Laure ;
Skakic, Vlado ;
Gogus, Feride ;
Sierakowski, Stanislaw ;
Bresnihan, Barry ;
Taylor, Peter ;
McClinton, Catherine ;
Pincus, Theodore .
ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (11) :1491-1496
[9]  
*WHO, TECHN APPR PROGR NAT
[10]   The disease activity score is not suitable as the sole criterion for initiation and evaluation of anti-tumor necrosis factor therapy in the clinic - Discordance between assessment measures and limitations in questionnaire use for regulatory purposes [J].
Wolfe, F ;
Michaud, K ;
Pincus, T ;
Furst, D ;
Keystone, E .
ARTHRITIS AND RHEUMATISM, 2005, 52 (12) :3873-3879
1